Rugera Simon P, Mudondo Hope, Tumusiime Jazira, Udu Rahma, Kiconco Ritah, Lumumba Sylvia A, Bagenda Charles N
Department of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Department of Pure and Applied Sciences, School of Applied and Health Sciences, Technical University of Mombasa, Mombasa, Kenya.
Afr J Lab Med. 2025 Feb 19;14(1):2565. doi: 10.4102/ajlm.v14i1.2565. eCollection 2025.
Hyperuricaemia is a risk factor for gout and independently predicts hypertension, diabetes, and chronic kidney disease development. While elevated uric acid levels occur in HIV patients, and weight gain is linked to dolutegravir-based therapy, data on the obesity-hyperuricaemia relationship in this population remain limited.
The objective of our study was to evaluate the association between obesity and hyperuricaemia among HIV-positive patients on antiretroviral therapy in South-Western Uganda.
Between April 2024 and June 2024, this study conducted a secondary analysis of data on uric acid level and factors associated with obesity from a 2023 cross-sectional study of HIV-positive participants. We used logistic regression to assess the factors associated with hyperuricaemia, and receiver operating characteristic curve analysis to assess the predictive performance of body mass index for hyperuricaemia.
Among 328 participants, hyperuricaemia prevalence was 23.48% (95% confidence interval [CI]: 19.19-28.39%) higher in male participants (31.6%) than female participants (20.0%, = 0.023). Overweight (adjusted odds ratio [aOR]: 2.01; 95% CI: 1.01-4.00; = 0.046), obesity (aOR: 2.50; 95% CI: 1.09-5.73, = 0.030), and male gender (aOR: 2.31; 95% CI: 1.07-5.01, = 0.033) were significantly associated with hyperuricaemia.
Our findings indicate a relationship between hyperuricaemia and obesity in HIV patients on antiretroviral therapy in Uganda. Nationwide studies using primary data are needed to better understand this relationship's epidemiological spread.
This study is the first to link obesity with hyperuricaemia among HIV-positive Ugandans on antiretroviral therapy, highlighting obesity as a key metabolic complication of HIV treatment.
高尿酸血症是痛风的危险因素，并且可独立预测高血压、糖尿病和慢性肾脏病的发生。虽然HIV患者尿酸水平会升高，且体重增加与基于多替拉韦的治疗有关，但该人群中肥胖与高尿酸血症关系的数据仍然有限。
我们研究的目的是评估乌干达西南部接受抗逆转录病毒治疗的HIV阳性患者中肥胖与高尿酸血症之间的关联。
在2024年4月至2024年6月期间，本研究对2023年一项HIV阳性参与者横断面研究中尿酸水平及与肥胖相关因素的数据进行了二次分析。我们使用逻辑回归评估与高尿酸血症相关的因素，并使用受试者工作特征曲线分析评估体重指数对高尿酸血症的预测性能。
在328名参与者中，男性参与者的高尿酸血症患病率为31.6%，高于女性参与者的20.0%（P = 0.023），患病率为23.48%（95%置信区间[CI]：19.19 - 28.39%）。超重（调整优势比[aOR]：2.01；95% CI：1.01 - 4.00；P = 0.046）、肥胖（aOR：2.50；95% CI：1.09 - 5.73，P = 0.030）和男性性别（aOR：2.31；95% CI：1.07 - 5.01，P = 0.033）与高尿酸血症显著相关。
我们的研究结果表明，乌干达接受抗逆转录病毒治疗的HIV患者中高尿酸血症与肥胖之间存在关联。需要使用原始数据进行全国性研究，以更好地了解这种关系的流行病学传播情况。
本研究首次将乌干达接受抗逆转录病毒治疗的HIV阳性者中的肥胖与高尿酸血症联系起来，突出了肥胖是HIV治疗的关键代谢并发症。
